-
-
-
-
-
-
-
Nuvalent begins NDA submission for cancer drug zidesamtinib
-
-
-
-
-
-
-
Nuvalent, Inc. (NUVL) Misses Q2 EPS by 12c
-
-
-
-
-
-
-
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results
-
-
-
-
-
-
-
Nuvalent Highlights Pipeline and Business Progress and Reports Fourth Quarter and Full Year 2022 Financial Results
-
-
-
-
-
-
-
Nuvalent Announces Business and Program Highlights and Reports Second Quarter 2021 Financial Results
1,168,522 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

